Next Article in Journal
Antiamoebic Activities of Indolocarbazole Metabolites Isolated from Streptomyces sanyensis Cultures
Next Article in Special Issue
Bright Spots in the Darkness of Cancer: A Review of Starfishes-Derived Compounds and Their Anti-Tumor Action
Previous Article in Journal
Anti-Inflammatory and Anti-Aging Evaluation of Pigment–Protein Complex Extracted from Chlorella Pyrenoidosa
Previous Article in Special Issue
The Phylum Bryozoa as a Promising Source of Anticancer Drugs
Open AccessArticle

Selective Inhibition of Liver Cancer Cells Using Venom Peptide

Department of Chemistry and Biochemistry, Hunter College, Belfer Research Building 413 East 69th Street, New York, NY 10021, USA
American Museum of Natural History, Central Park West at 79th St, New York, NY 10024, USA
CUNY Graduate Center Chemistry, Biology, Biochemistry Programs, 365 5th Ave, New York, NY 10016, USA
Weill Cornell Medicine (Biochemistry Department), 1300 York Avenue, New York, NY 10065, USA
Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, 1300 York Avenue, New York, NY 10065, USA
Department of Biological Sciences, Hunter College, 695 Park Avenue, New York, NY 10065, USA
Author to whom correspondence should be addressed.
Mar. Drugs 2019, 17(10), 587;
Received: 7 September 2019 / Revised: 9 October 2019 / Accepted: 11 October 2019 / Published: 17 October 2019
(This article belongs to the Special Issue Antitumor Compounds from Marine Invertebrates)
Increasingly cancer is being viewed as a channelopathy because the passage of ions via ion channels and transporters mediate the regulation of tumor cell survival, death, and motility. As a result, a potential targeted therapy for cancer is to use venom peptides that are selective for ion channels and transporters overexpressed in tumor cells. Here we describe the selectivity and mechanism of action of terebrid snail venom peptide, Tv1, for treating the most common type of liver cancer, hepatocellular carcinoma (HCC). Tv1 inhibited the proliferation of murine HCC cells and significantly reduced tumor size in Tv1-treated syngeneic tumor-bearing mice. Tv1’s mechanism of action involves binding to overexpressed transient receptor potential (TRP) channels leading to calcium dependent apoptosis resulting from down-regulation of cyclooxygenase-2 (COX-2). Our findings demonstrate the importance of modulating ion channels and the unique potential of venom peptides as tumor specific ligands in the quest for targeted cancer therapies. View Full-Text
Keywords: venom peptide; liver cancer; terebrid snail; TRP channel; Cox-2 venom peptide; liver cancer; terebrid snail; TRP channel; Cox-2
Show Figures

Figure 1

MDPI and ACS Style

Anand, P.; Filipenko, P.; Huaman, J.; Lyudmer, M.; Hossain, M.; Santamaria, C.; Huang, K.; Ogunwobi, O.O.; Holford, M. Selective Inhibition of Liver Cancer Cells Using Venom Peptide. Mar. Drugs 2019, 17, 587.

AMA Style

Anand P, Filipenko P, Huaman J, Lyudmer M, Hossain M, Santamaria C, Huang K, Ogunwobi OO, Holford M. Selective Inhibition of Liver Cancer Cells Using Venom Peptide. Marine Drugs. 2019; 17(10):587.

Chicago/Turabian Style

Anand, Prachi; Filipenko, Petr; Huaman, Jeannette; Lyudmer, Michael; Hossain, Marouf; Santamaria, Carolina; Huang, Kelly; Ogunwobi, Olorunseun O.; Holford, Mandë. 2019. "Selective Inhibition of Liver Cancer Cells Using Venom Peptide" Mar. Drugs 17, no. 10: 587.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop